Head to Head Analysis: Solid Biosciences (NASDAQ:SLDB) vs. Gritstone Oncology (NASDAQ:GRTS)

Share on StockTwits

Gritstone Oncology (NASDAQ:GRTS) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Valuation and Earnings

This table compares Gritstone Oncology and Solid Biosciences’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gritstone Oncology $1.19 million 234.49 -$64.78 million ($7.26) -1.07
Solid Biosciences N/A N/A -$74.80 million ($2.25) -4.90

Gritstone Oncology has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Gritstone Oncology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gritstone Oncology and Solid Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gritstone Oncology -2,038.71% -83.79% -42.53%
Solid Biosciences N/A -87.96% -76.46%

Analyst Ratings

This is a breakdown of recent ratings for Gritstone Oncology and Solid Biosciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gritstone Oncology 0 0 6 0 3.00
Solid Biosciences 3 1 4 0 2.13

Gritstone Oncology currently has a consensus price target of $21.25, suggesting a potential upside of 172.44%. Solid Biosciences has a consensus price target of $10.50, suggesting a potential downside of 4.81%. Given Gritstone Oncology’s stronger consensus rating and higher possible upside, analysts plainly believe Gritstone Oncology is more favorable than Solid Biosciences.

Institutional and Insider Ownership

77.7% of Gritstone Oncology shares are held by institutional investors. Comparatively, 45.7% of Solid Biosciences shares are held by institutional investors. 38.0% of Gritstone Oncology shares are held by insiders. Comparatively, 31.2% of Solid Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Gritstone Oncology has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500.

Summary

Gritstone Oncology beats Solid Biosciences on 10 of the 13 factors compared between the two stocks.

Gritstone Oncology Company Profile

Gritstone Oncology Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.

Solid Biosciences Company Profile

Solid Biosciences Inc., a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a monoclonal antibody that is in preclinical trials to reduce fibrosis and inflammation. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits to DMD patients. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.